Probi will manufacture Blis’s bacterial strains and sell them to Probi customers. The two companies will also collaborate on research and development.
Probiotic ingredients supplier Probi (Sweden) has entered into a strategic partnership with another probiotics supplier, Blis Technologies Ltd. (New Zealand), which innovates probiotic strains for oral health. Probi has invested NZD 9 million in newly issued shares in Blis Technologies, now holding 13% ownership. Blis Technologies’ clinically documented bacterial strains support natural immune defenses, prevent mouth and throat infections, and support healthy teeth and gums.
The two companies have signed a licensing and distribution agreement. Probi will manufacture Blis’s bacterial strains and sell them to Probi customers. The two companies will also collaborate on research and development. Probi plans to begin producing Blis products in Q4 of this year and introduce Blis bacterial strains in its own portfolio in the fall.
“This is a very exciting partnership for Probi…” said Tom Rönnlund, Probi’s CEO, in a press release. “Through this partnership, we will be able to broaden our portfolio with more health areas and strengthen our position with clinically documented bacterial strains. At the same time, we can utilize our greater production capacity and thereby contribute to higher profitability for both Probi and Blis.”
Brian Watson, CEO of Blis Technologies, said, “With Probi, we get a strong partner who can offer high-quality production of our probiotic strains and who has a strong position in the American market where we see great potential for our products.”